---
title: "Latent-Y: The Autonomous AI Agent for Drug Design at Scale"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280123205.md"
description: "Today, Latent Labs introduced Latent-Y, an AI agent that can create therapeutic antibodies from a text prompt, drastically reducing the time needed for expert work from weeks to hours. Latent-Y operates using Latent-X2, the cutting-edge model by Latent Labs for designing drug-like antibodies and peptides, democratizing structural drug design for researchers without the need for specialized infrastructure. Latent Labs is granting access to chosen partners for Latent-Y, a tool that amplifies efficiency in drug discovery."
datetime: "2026-03-23T08:02:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280123205.md)
  - [en](https://longbridge.com/en/news/280123205.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280123205.md)
---

# Latent-Y: The Autonomous AI Agent for Drug Design at Scale

Today, Latent Labs introduced Latent-Y, an AI agent that can create therapeutic antibodies from a text prompt, drastically reducing the time needed for expert work from weeks to hours. Latent-Y operates using Latent-X2, the cutting-edge model by Latent Labs for designing drug-like antibodies and peptides, democratizing structural drug design for researchers without the need for specialized infrastructure. Latent Labs is granting access to chosen partners for Latent-Y, a tool that amplifies efficiency in drug discovery.

### Related Stocks

- [MDLB.US](https://longbridge.com/en/quote/MDLB.US.md)

## Related News & Research

- [15:05 ETBioLab Holdings Earns Great Place to Work® Certification](https://longbridge.com/en/news/281067196.md)
- [MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue](https://longbridge.com/en/news/281013175.md)